Skip to content
Head to head

BridgeBio Pharma vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: BBIO · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

BBIO +13.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
BBIOVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price76.03515.02
Change today-2.75%-1.08%
1-year return+17.7%+22.0%
Market cap$14.81B$130.58B
52-week range62.50 – 93.42412.27 – 568.67
Valuation
P/E (TTM)-25.0933.14
P/E percentile, own 5-yr range1st99th
P/B-5.696.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.7815.32
Net profit (TTM)$-736.35M$3.88B
Revenue (TTM)$945.54M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+192.6%+11.8%
Gross margin94.3%85.5%
Operating margin-37.3%33.1%
Net margin-62.6%30.7%
Free cash flow (TTM)$-369.81M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership100.9%96.8%
Insider activity (12mo)26 buy / 24 sell28 buy / 22 sell
Short interest (% of float)10.7%1.9%
Analyst consensus94% buy / 6% hold (16)95% buy / 5% hold (21)
Analyst price target$110 (+45%)$624 (+21%)
StockVane view
StockVane Quant RatingC (60)C (68)
Company
Employees8396,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.